Table 4

Effect of PPAR-γ agonists on inflammatory genes levels in the knee synovium of arthritic rats

Groups

IL-1

TNF-α

VEGF

bFGF

MCP-1

Normal controls

0.23 ± 0.20

0.13 ± 0.07

1.39 ± 0.01

0.41 ± 0.18

0.26 ± 0.14

AIA controls

1.40 ± 0.29*

1.19 ± 0.19*

3.40 ± 1.05*

5.24 ± 0.35*

1.05 ± 0.18*

AIA + ROSI 10

0.98 ± 0.06

1.39 ± 0.16

3.79 ± 0.28

4.59 ± 0.77

1.51 ± 0.22

AIA + PIO 30

0.66 ± 0.16^#

0.37 ± 0.11^#

4.67 ± 0.21

2.18 ± 0.61^#

1.51 ± 0.21

PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; MCP-1, monocyte chemotactic protein-1. Data are expressed as means ± SEM of mRNAs of the gene of interest over L27 mRNA (n = 3 representative samples per group).

*, P < 0.05 compared with normal controls; ^#, P < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD test).

Koufany et al. Arthritis Research & Therapy 2008 10:R6   doi:10.1186/ar2354